Table 2.
Characteristics, treatment and outcomes of VRE bloodstream infections
| Characteristic | |
|---|---|
| E. faecium | 96 (100%) |
| vanB | 95 (99%) |
| Patients with multiple episodes of VRE BSI | 10 (10%) |
| Polymicrobial BSI | 23 (24%) |
| Gram negative bacilli | 9 (9%) |
| Candida sp. | 4 (4%) |
| Coagulase negative staphylococci | 10 (10%) |
| VRE screened prior to BSI | 72 (75%) |
| Positive | 49/72 (68%) |
| Treated with VRE active agenta | 88/95 (93%) |
| Teicoplanin therapy alone | 59/95 (62%) |
| Linezolid therapy alone | 6/95 (6%) |
| Daptomycin therapy alone | 2/95 (2%) |
| Sequential therapy | 21/95 (22%) |
| ICU admission within 48 h of BSI | 15 (16%) |
| Death at 7 days | 8 (8%) |
| Death at 30 days | 30 (31%) |
| Length of stay post BSI, median (days) | 18 (range 1–78) |
| Length of stay total, median (days) | 38.5 (range 2–138) |
VRE Vancomycin resistant Enterococci, BSI Blood stream infection, ICU Intensive care unit
aData not available for 1 patient